Vol. 34, No. 6, 2011
Issue release date: November 2011
Free Access
Kidney Blood Press Res 2011;34:404–417
(DOI:10.1159/000328332)
Review
Add to my selection

Calcium, Vitamin D and Cardiovascular Disease

Guessous I.a, b · Bochud M.b · Bonny O.c · Burnier M.c
aUnit of Population Epidemiology, Division of Primary Care Medicine, Department of Community Medicine, Primary Care and Emergency Medicine, Geneva University Hospitals, Geneva, bCommunity Prevention Unit, University Institute of Social and Preventive Medicine (IUMSP), and cDepartment of Medicine, Service of Nephrology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
email Corresponding Author


 goto top of outline Key Words

  • Calcium
  • Cardiovascular disease
  • Vitamin D

 goto top of outline Abstract

The relationship between calcium and cardiovascular diseases (CVD) has been explored for a long time. Studies exploring the effect of calcium intake or calcium supplementation on cardiovascular risk suggest that systolic blood pressure increases under low calcium intake and decreases with calcium supplementation. A lower calcium intake has been associated with an increased risk of stroke. However, the impact of calcium supplementation on stroke risk remains unclear. Calcium supplementation may increase the risk of myocardial infarction. The relationship between vitamin D and CVD has been explored more recently. Negative correlations between vitamin D levels and the risk of hypertension, myocardial infarction, and stroke have been reported in several observational studies. The effect of vitamin D supplementation on blood pressure is still unclear and no effect of vitamin D supplementation on coronary heart disease or stroke has been clearly demonstrated. There is a lack of randomized clinical trials primarily addressing the effect of these parameters on CVD. Therefore, the real impact of calcium and vitamin D on cardiovascular outcomes remains to be documented by appropriate experimental data.

Copyright © 2011 S. Karger AG, Basel


 goto top of outline References
  1. Allender PS, et al: Dietary calcium and blood pressure: a meta-analysis of randomized clinical trials. Ann Intern Med 1996;124:825–831.
  2. Bucher HC, et al: Effects of dietary calcium supplementation on blood pressure. A meta-analysis of randomized controlled trials. JAMA 1996;275:1016–1022.
  3. Cappuccio FP, Siani A, Strazzullo P: Oral calcium supplementation and blood pressure: an overview of randomized controlled trials. J Hypertens 1989;7:941–946.
  4. Dickinson HO, et al: Calcium supplementation for the management of primary hypertension in adults. Cochrane Database Syst Rev 2006;CD004639.
  5. Griffith LE, et al: The influence of dietary and nondietary calcium supplementation on blood pressure: an updated meta-analysis of randomized controlled trials. Am J Hypertens 1999;12:84–92.
  6. Van Mierlo LA, et al: Blood pressure response to calcium supplementation: a meta-analysis of randomized controlled trials. J Hum Hypertens 2006;20:571–580.
  7. Chung M, et al: Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess (Full Rep) 2009;183:1–420.

    External Resources

  8. Miller GD, et al: Benefits of dairy product consumption on blood pressure in humans: a summary of the biomedical literature. J Am Coll Nutr 2000;19(suppl):147S–164S.

    External Resources

  9. Alonso A, et al: Low-fat dairy consumption and reduced risk of hypertension: the Seguimiento Universidad de Navarra (SUN) cohort. Am J Clin Nutr 2005;82:972–979.
  10. Ascherio A, et al: A prospective study of nutritional factors and hypertension among US men. Circulation 1992;86:1475–1484.
  11. Dwyer JH, et al: Dietary calcium, alcohol, and incidence of treated hypertension in the NHANES I epidemiologic follow-up study. Am J Epidemiol 1996;144:828–838.
  12. Ford ES, Cooper RS: Risk factors for hypertension in a national cohort study. Hypertension 1991;18:598–606.
  13. Wang L, et al: Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension 2008;51:1073–1079.
  14. Ascherio A, et al: Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension 1996;27:1065–1072.
  15. Schatzkin A, et al: A comparison of a food frequency questionnaire with a 24-hour recall for use in an epidemiological cohort study: results from the biomarker-based Observing Protein and Energy Nutrition (OPEN) study. Int J Epidemiol 2003;32:1054–1062.
  16. Bulpitt CJ, Hodes C, Everitt MG: The relationship between blood pressure and biochemical risk factors in a general population. Br J Prev Soc Med 1976;30:158–162.
  17. Vargas CM, Obisesan T, Gillum RF: Association of serum albumin concentration, serum ionized calcium concentration, and blood pressure in the Third National Health and Nutrition Examination Survey. J Clin Epidemiol 1998;51:739–746.
  18. Fogh-Andersen N, et al: Sex-dependent relation between ionized calcium in serum and blood pressure. Clin Chem 1984;30:116–118.
  19. Buckley BM, et al: Lack of evidence of low ionized calcium levels in systemic hypertension. Am J Cardiol 1987;59:878–880.
  20. Jorde R, et al: Serum calcium and cardiovascular risk factors and diseases: the Tromsø study. Hypertension 1999;34:484–490.
  21. Lind L, et al: Relation of serum calcium concentration to metabolic risk factors for cardiovascular disease. BMJ 1988;297:960–963.
  22. Phillips AN, Shaper AG: Serum calcium and blood pressure. J Hum Hypertens 1991;5:479–484.
  23. Ogard CG, et al: Serum ionised calcium and cardiovascular disease in 45-year-old men and women followed for 18 years. Eur J Epidemiol 2006;21:123–127.
  24. Jorde R, Bonaa KH, Sundsfjord J: Population-based study on serum ionised calcium, serum parathyroid hormone, and blood pressure. The Tromsø study. Eur J Endocrinol 1999;141:350–357.
  25. Kesteloot H, Joossens JV: Relationship of serum sodium, potassium, calcium, and phosphorus with blood pressure. Belgian Interuniversity Research on Nutrition and Health. Hypertension 1988;12:589–593.
  26. Hunt SC, Williams RR, Kuida H: Different plasma ionized calcium correlations with blood pressure in high and low renin normotensive adults in Utah. Am J Hypertens 1991;4:1–8.
  27. McCarron DA: Low serum concentrations of ionized calcium in patients with hypertension. N Engl J Med 1982;307:226–228.
  28. Resnick LM: The role of dietary calcium in hypertension: a hierarchical overview. Am J Hypertens 1999;12:99–112.
  29. Zemel MB: Calcium modulation of hypertension and obesity: mechanisms and implications. J Am Coll Nutr 2001;20(suppl):428S–435S, 440S–442S.

    External Resources

  30. Zemel MB: Nutritional and endocrine modulation of intracellular calcium: implications in obesity, insulin resistance and hypertension. Mol Cell Biochem 1998;188:129–136.
  31. Bohr DF: Vascular smooth muscle: dual effect of calcium. Science 1963;139:597–599.
  32. Ledoux J, et al: Calcium-activated potassium channels and the regulation of vascular tone. Physiology (Bethesda) 2006;21:69–78.
  33. Iwamoto T, et al: Salt-sensitive hypertension is triggered by Ca2+ entry via Na+/Ca2+ exchanger type-1 in vascular smooth muscle. Nat Med 2004;10:1193–1199.
  34. Zulian A, et al: Up-regulation of Na+/Ca2+ exchanger and TRPC6 contributes to abnormal Ca2+ homeostasis in arterial smooth muscle cells from Milan hypertensive rats. Am J Physiol Heart Circ Physiol 2010;299:H624–H633.
  35. Levy D, et al: Genome-wide association study of blood pressure and hypertension. Nat Genet 2009;41:677–687.
  36. Resnick LM, et al: Divalent cations in essential hypertension. Relations between serum ionized calcium, magnesium, and plasma renin activity. N Engl J Med 1983;309:888–891.
  37. Touyz RM, Panz V, Milne FJ: Relations between magnesium, calcium, and plasma renin activity in black and white hypertensive patients. Miner Electrolyte Metab 1995;21:417–422.
  38. Maillard MP, et al: Calcium-sensing receptors modulate renin release in vivo and in vitro in the rat. J Hypertens 2009;27:1980–1987.
  39. Bolland MJ, et al: Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. BMJ 2008;336:262–266.
  40. Grant AM, et al: Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlled trial. Lancet 2005;365:1621–1628.
  41. Hsia J, et al: Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007;115:846–854.
  42. Prince RL, et al: Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch Intern Med 2006;166:869–875.
  43. Bolland MJ, et al: Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691.
  44. Al-Delaimy WK, et al: A prospective study of calcium intake from diet and supplements and risk of ischemic heart disease among men. Am J Clin Nutr 2003;77:814–818.
  45. Bostick RM, et al: Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. Am J Epidemiol 1999;149:151–161.
  46. Marniemi J, et al: Dietary and serum vitamins and minerals as predictors of myocardial infarction and stroke in elderly subjects. Nutr Metab Cardiovasc Dis 2005;15:188–197.
  47. Umesawa M, et al: Dietary intake of calcium in relation to mortality from cardiovascular disease: the JACC Study. Stroke 2006;37:20–26.
  48. Umesawa M, et al: Dietary calcium intake and risks of stroke, its subtypes, and coronary heart disease in Japanese: the JPHC Study Cohort I. Stroke 2008;39:2449–2456.
  49. Van der Vijver LP, et al: Calcium intake and 28-year cardiovascular and coronary heart disease mortality in Dutch civil servants. Int J Epidemiol 1992;21:36–39.
  50. Palmer M, et al: Survival and renal function in untreated hypercalcemia: population-based cohort study with 14 years of follow-up. Lancet 1987;1:59–62.
  51. Leifsson BG, Ahren B: Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab 1996;81:2149–2153.
  52. Lind L, et al: Serum calcium: a new, independent, prospective risk factor for myocardial infarction in middle-aged men followed for 18 years. J Clin Epidemiol 1997;50:967–973.
  53. Larsson SC, et al: Magnesium, calcium, potassium, and sodium intakes and risk of stroke in male smokers. Arch Intern Med 2008;168:459–465.
  54. Carlson LA, et al: Effects of oral calcium upon serum cholesterol and triglycerides in patients with hyperlipidemia. Atherosclerosis 1971;14:391–400.
  55. Karanja N, et al: Plasma lipids and hypertension: response to calcium supplementation. Am J Clin Nutr 1987;45:60–65.
  56. De Bacquer D, et al: Epidemiological evidence for an association between serum calcium and serum lipids. Atherosclerosis 1994;108:193–200.
  57. Reid IR, et al: Effects of calcium supplementation on serum lipid concentrations in normal older women: a randomized controlled trial. Am J Med 2002;112:343–347.
  58. Wareham NJ, et al: Glucose intolerance is associated with altered calcium homeostasis: a possible link between increased serum calcium concentration and cardiovascular disease mortality. Metabolism 1997;46:1171–1177.
  59. Sun G, et al: Altered calcium homeostasis is correlated with abnormalities of fasting serum glucose, insulin resistance, and β-cell function in the Newfoundland population. Diabetes 2005;54:3336–3339.
  60. Renaud S, et al: Platelet functions in relation to diet and serum lipids in British farmers. Br Heart J 1981;46:562–570.
  61. Renaud S, et al: Nutrients, platelet function and composition in nine groups of French and British farmers. Atherosclerosis 1986;60:37–48.
  62. Larsson TE, et al: Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 2010;30:333–339.
  63. Tonelli M, et al: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627–2633.
  64. Detrano R, et al: Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336–1345.
  65. Weintraub WS, Diamond GA: Predicting cardiovascular events with coronary calcium scoring. N Engl J Med 2008;358:1394–1396.
  66. Manson JE, et al: Calcium/vitamin D supplementation and coronary artery calcification in the Women’s Health Initiative. Menopause 2010;17:683–691.

    External Resources

  67. Reid IR, Bolland MJ, Grey A: Does calcium supplementation increase cardiovascular risk? Clin Endocrinol (Oxf) 2010;73:689–695.
  68. Ascherio A, et al: Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation 1998;98:1198–1204.
  69. Iso H, et al: Prospective study of calcium, potassium, and magnesium intake and risk of stroke in women. Stroke 1999;30:1772–1779.
  70. Ross RK, et al: Prospective evaluation of dietary and other predictors of fatal stroke in Shanghai, China. Circulation 1997;96:50–55.
  71. Weng LC, et al: Is ischemic stroke risk related to folate status or other nutrients correlated with folate intake? Stroke 2008;39:3152–3158.
  72. Ovbiagele B, et al: Are elevated admission calcium levels associated with better outcomes after ischemic stroke? Neurology 2006;67:170–173.
  73. Ovbiagele B, et al: Serum calcium as prognosticator in ischemic stroke. Stroke 2008;39:2231–2236.
  74. Peuler JD, Schelper RL: Partial protection from salt-induced stroke and mortality by high oral calcium in hypertensive rats. Stroke 1992;23:532–538.
  75. Pfeifer M, et al: Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001;86:1633–1637.
  76. Nagpal J, Pande JN, Bhartia A: A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 2009;26:19–27.
  77. Scragg R, Khaw KT, Murphy S: Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr 1995;49:640–646.
  78. Krause R, et al: Ultraviolet B and blood pressure. Lancet 1998;352:709–710.
  79. Joffres MR, Reed DM, Yano K: Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. Am J Clin Nutr 1987;45:469–475.
  80. Sowers MR, Wallace RB, Lemke JH: The association of intakes of vitamin D and calcium with blood pressure among women. Am J Clin Nutr 1985;42:135–142.
  81. Scragg R, Sowers M, Bell C: Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the Third National Health and Nutrition Examination Survey. Am J Hypertens 2007;20:713–719.
  82. Hypponen E, et al: 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008;57:298–305.
  83. Hintzpeter B, et al: Vitamin D status and health correlates among German adults. Eur J Clin Nutr 2008;62:1079–1089.
  84. Snijder MB, et al: Vitamin D status and parathyroid hormone levels in relation to blood pressure: a population-based study in older men and women. J Intern Med 2007;261:558–565.
  85. Scragg R, et al: Plasma 25-hydroxyvitamin D3 and its relation to physical activity and other heart disease risk factors in the general population. Ann Epidemiol 1992;2:697–703.
  86. Scragg R, Khaw KT, Murphy S: Lifestyle factors associated with winter serum 25-hydroxyvitamin D levels in elderly adults. Age Ageing 1995;24:271–275.
  87. Lind L, et al: Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens 1995;8:894–901.
  88. Scragg R, et al: Serum 25-hydroxycholecalciferol concentration in newly detected hypertension. Am J Hypertens 1995;8:429–432.
  89. Rueda S, et al: Vitamin D, PTH, and the metabolic syndrome in severely obese subjects. Obes Surg 2008;18:151–154.
  90. Reis JP, et al: Vitamin D, parathyroid hormone levels, and the prevalence of metabolic syndrome in community-dwelling older adults. Diabetes Care 2007;30:1549–1555.
  91. Argiles A: Blood pressure is correlated with vitamin D3 serum levels in dialysis patients. Blood Purif 2002;20:370–375.
  92. Brickmann AS, et al: Calcitropic hormones, platelet calcium, and blood pressure in essential hypertension. Hypertension 1990;16:515–522.
  93. Kokot F, et al: Influence of ultraviolet irradiation on plasma vitamin D and calcitonin levels in humans. Kidney Int Suppl 1989;27:S143–S146.
  94. Muray S, et al: Influence of vitamin D receptor gene polymorphisms and 25-hydroxyvitamin D on blood pressure in apparently healthy subjects. J. Hypertens 2003;21:2069–2075.
  95. Forouhi NG, et al: Baseline serum 25-hydroxyvitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes 2008;57:2619–2625.
  96. Forman JP, et al: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension 2007;49:1063–1069.
  97. Forman JP, Curhan GC, Taylor EN: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension among young women. Hypertension 2008;52:828–832.
  98. Jorde R, et al: Serum 25-hydroxyvitamin D levels are strongly related to systolic blood pressure but do not predict future hypertension. Hypertension 2010;55:792–798.
  99. Jorde R, Svartberg J, Sundsfjord J: Serum parathyroid hormone as a predictor of increase in systolic blood pressure in men. J Hypertens 2005;23:1639–1644.
  100. Xiang W, et al: Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005;288:E125–E132.
  101. Kong J, et al: Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int 2008;74:1577–1581.
  102. Bonizzi G, Karin M: The two NF-ĸB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004;25:280–288.
  103. Guijarro C, Egido J: Transcription factor-ĸB (NF-ĸB) and renal disease. Kidney Int 2001;59:415–424.
  104. Pilz S, et al: Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 2009;6:621–630.
  105. Wong MS, et al: Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2008;295:H289–H296.
  106. Talmor Y, et al: Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am J Physiol Renal Physiol 2008;294:F1059–F1064.
  107. Richart T, Li Y, Staessen JA: Renal versus extrarenal activation of vitamin D in relation to atherosclerosis, arterial stiffening, and hypertension. Am J Hypertens 2007;20:1007–1015.
  108. Grimes DS, Hindle E, Dyer T: Sunlight, cholesterol and coronary heart disease. QJM 1996;89:579–589.
  109. Douglas AS, et al: Seasonal variation in coronary heart disease in Scotland. J Epidemiol Community Health 1995;49:575–582.
  110. Trivedi DP, Doll R, Khaw KT: Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double-blind controlled trial. BMJ 2003;326:469.
  111. LaCroix AZ, et al: Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women’s Health Initiative calcium-vitamin D randomized controlled trial. J Gerontol A Biol Sci Med Sci 2009;64:559–567.
  112. Wang TJ, et al: Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008;117:503–511.
  113. Dobnig H, et al: Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168:1340–1349.
  114. Kendrick J, et al: 25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the third national health and nutrition examination survey. Atherosclerosis 2009;205:255–260.
  115. Melamed ML, et al: 25-Hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008;168:1629–1637.
  116. Kim DH, et al: Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008;102:1540–1544.
  117. Rajasree S, et al: Serum 25-hydroxyvitamin D3 levels are elevated in South Indian patients with ischemic heart disease. Eur J Epidemiol 2001;17:567–571.
  118. Scragg R, et al: Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol 1990;19:559–563.
  119. Giovannucci E, et al: 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008;168:1174–1180.
  120. Zittermann A, Schleithoff SS, Koerfer R: Putting cardiovascular disease and vitamin D insufficiency into perspective. Br J Nutr 2005;94:483–492.
  121. Rashid G, et al: Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor. Eur J Clin Invest 2008;38:798–803.
  122. Judd SE, Tangpricha V: Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci 2009;338:40–44.
  123. O’Connell TD, et al: 1,25-Dihydroxyvitamin D3 regulation of cardiac myocyte proliferation and hypertrophy. Am J Physiol 1997;272:H1751–H1758.
  124. Watson KE, et al: Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation 1997;96:1755–1760.
  125. Penckofer S, et al: Vitamin D and diabetes: let the sunshine in. Diabetes Educ 2008;34:939–940, 942, 944 passim.
  126. Pittas AG, et al: The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007;92:2017–2029.
  127. Poole KE, et al: Reduced vitamin D in acute stroke. Stroke 2006;37:243–245.
  128. Pilz S, et al: Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke 2008;39:2611–2613.
  129. Teng M, et al: Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003;349:446–456.
  130. Teng M, et al: Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005;16:1115–1125.
  131. Kalantar-Zadeh K, et al: Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771–780.
  132. Tentori F, et al: Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 2006;70:1858–1865.
  133. Palmer SC, et al: Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 2007;147:840–853.
  134. Agarwal R, et al: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005;68:2823–2828.
  135. Alborzi P, et al: Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008;52:249–255.
  136. Fishbane S, et al: Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009;54:647–652.
  137. Melamed ML, et al: 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol 2009;20:2631–2639.
  138. Zittermann A, et al: Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003;41:105–112.
  139. Cooper R, et al: Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: findings of the national conference on cardiovascular disease prevention. Circulation 2000;102:3137–3147.
  140. Pearce N: Commentary: The rise and rise of corporate epidemiology and the narrowing of epidemiology’s vision. Int J Epidemiol 2007;36:713–717.

 goto top of outline Author Contacts

Dr. Idris Guessous
Community Prevention Unit
University Institute of Social and Preventive Medicine (IUMSP)
Rue du Bugnon 17, CH–1005 Lausanne (Switzerland)
Tel. +41 21 314 72 76, E-Mail idris.guessous@chuv.ch


 goto top of outline Article Information

Published online: June 11, 2011
Number of Print Pages : 14
Number of Figures : 2, Number of Tables : 6, Number of References : 140


 goto top of outline Publication Details

Kidney and Blood Pressure Research

Vol. 34, No. 6, Year 2011 (Cover Date: November 2011)

Journal Editor: Tesar V. (Prague)
ISSN: 1420-4096 (Print), eISSN: 1423-0143 (Online)

For additional information: http://www.karger.com/KBR


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.